Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tetratricopeptide repeat domain 3 (TTC3) is a protein encoded by the *TTC3* gene located on human chromosome 21q22.2, within the Down syndrome critical region. TTC3 contains multiple tetratricopeptide repeat (TPR) motifs and a RING finger domain, conferring its function as an E3 ubiquitin-protein ligase involved in protein ubiquitination and proteasomal degradation. It interacts with chaperones such as Hsp70 and targets substrates including phosphorylated Akt and DNA polymerase γ (POLG), affecting mitochondrial protein homeostasis. TTC3 is developmentally regulated and highly expressed in the nervous system; dysregulation or copy number variants have been linked to Down syndrome and may contribute to neurodegenerative pathologies through impaired protein homeostasis and aggregate formation[2][4].
Poly-ubiquitination of substrate proteins (e.g., phosphorylated Akt); Regulation of protein degradation (DNA polymerase γ/POLG) via interaction and ubiquitination machinery; Potential co-chaperone activities with Hsp70
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetratricopeptide repeat domain 3 (TTC3).